What is the maximum amount Jazz will repurchase in this concurrent offering?

Jazz expects to repurchase up to $225.0 million of ordinary shares concurrently with the pricing of the $1.0 billion exchangeable senior notes offering. The repurchases will be conducted in privately negotiated transactions with note purchasers at the closing price on the offering date.

How will these repurchases be funded?

The concurrent share repurchases will be funded with existing cash on hand. The company stated it has sufficient liquidity available for these transactions without requiring additional borrowing.

How does this relate to Jazz's prior share repurchase authorization?

These concurrent repurchases are part of Jazz Pharmaceuticals' share repurchase program announced in July 2024. Any amount repurchased will reduce the remaining authorized balance under that program. However, the filing does not disclose the total remaining authorization amount.

Is the share repurchase guaranteed to occur?

No. The filing explicitly states: 'No assurance can be given as to how many, if any, of the ordinary shares will be repurchased or the terms on which they will be repurchased.' The press release does not constitute an offer to repurchase, and the notes offering is not contingent on any share repurchase occurring.

What could the buyback's impact on share price be?

Jazz acknowledged that the concurrent repurchases could increase or reduce the size of any decrease in the market price of ordinary shares, potentially affecting the exchange price for the notes. However, the company stated it cannot predict the magnitude of such market activity or overall effects.

Why is Jazz repurchasing shares concurrent with a debt offering?

The filing states the $1.0 billion in net proceeds will be used for general corporate purposes. Executing repurchases concurrently with debt issuance allows the company to manage its capital structure and return value to shareholders while financing operations, though the mechanics and strategic rationale are not detailed in this announcement.

JAZZ 8-K Filed 2026-08-31 Execution disclosure

Jazz Pharmaceuticals to repurchase up to $225M shares concurrently with debt offering

Private $1B exchangeable notes offering paired with concurrent $225M share repurchase program execution

MechanismPrivately negotiated transacti

What the filing says

Jazz Pharmaceuticals plc announced on August 26, 2026, that it intends to offer $1.0 billion aggregate principal amount of exchangeable senior notes due 2032 in a private offering to qualified institutional buyers. Concurrently, the company expects to repurchase up to $225.0 million of its ordinary shares from purchasers of the notes in privately negotiated transactions.

The concurrent share repurchases will be executed at the closing price per ordinary share on the date of the offering and will be funded with existing cash on hand. These repurchases are being executed as part of Jazz Pharmaceuticals' share repurchase program announced in July 2024, with the $225 million reducing the remaining amount authorized under that program.

The company noted that no assurance can be given as to how many, if any, ordinary shares will be repurchased or the terms on which they will be repurchased. The concurrent repurchases could impact the market price of ordinary shares and the effective exchange price for the notes, though the company stated it cannot predict the magnitude of such market activity.

Jazz Pharmaceuticals also expects to repurchase up to $225.0 million of its ordinary shares from purchasers of the notes in privately negotiated transactions with or through one of the initial purchasers or its affiliate concurrently with the pricing of the offering (the "concurrent ordinary share repurchases"). — Jazz Pharmaceuticals plc 8-K filing · View on SEC EDGAR →

What this means

Jazz Pharmaceuticals is executing a $225 million share repurchase concurrently with a $1.0 billion exchangeable debt offering. The repurchases will be conducted through private transactions with note purchasers at the closing price on the offering date, using existing cash on hand. These repurchases reduce the remaining balance of the company's July 2024 authorization. The filing emphasizes that the concurrent buyback is discretionary—the company provides no assurance regarding execution—and that share repurchase activity could influence the market price of ordinary shares and the effective exchange price of the notes.

Frequently asked questions

What is the maximum amount Jazz will repurchase in this concurrent offering?: Jazz expects to repurchase up to $225.0 million of ordinary shares concurrently with the pricing of the $1.0 billion exchangeable senior notes offering. The repurchases will be conducted in privately negotiated transactions with note purchasers at the closing price on the offering date.
How will these repurchases be funded?: The concurrent share repurchases will be funded with existing cash on hand. The company stated it has sufficient liquidity available for these transactions without requiring additional borrowing.
How does this relate to Jazz's prior share repurchase authorization?: These concurrent repurchases are part of Jazz Pharmaceuticals' share repurchase program announced in July 2024. Any amount repurchased will reduce the remaining authorized balance under that program. However, the filing does not disclose the total remaining authorization amount.
Is the share repurchase guaranteed to occur?: No. The filing explicitly states: 'No assurance can be given as to how many, if any, of the ordinary shares will be repurchased or the terms on which they will be repurchased.' The press release does not constitute an offer to repurchase, and the notes offering is not contingent on any share repurchase occurring.
What could the buyback's impact on share price be?: Jazz acknowledged that the concurrent repurchases could increase or reduce the size of any decrease in the market price of ordinary shares, potentially affecting the exchange price for the notes. However, the company stated it cannot predict the magnitude of such market activity or overall effects.
Why is Jazz repurchasing shares concurrent with a debt offering?: The filing states the $1.0 billion in net proceeds will be used for general corporate purposes. Executing repurchases concurrently with debt issuance allows the company to manage its capital structure and return value to shareholders while financing operations, though the mechanics and strategic rationale are not detailed in this announcement.

execution concurrent-offering exchangeable-notes rule-144a pharmaceutical private-placement

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.